AR082411A1 - siRNA DIRIGIDO AL VEGFA Y METODOS DE TRATAMIENTO IN VIVO - Google Patents
siRNA DIRIGIDO AL VEGFA Y METODOS DE TRATAMIENTO IN VIVOInfo
- Publication number
- AR082411A1 AR082411A1 ARP110102737A ARP110102737A AR082411A1 AR 082411 A1 AR082411 A1 AR 082411A1 AR P110102737 A ARP110102737 A AR P110102737A AR P110102737 A ARP110102737 A AR P110102737A AR 082411 A1 AR082411 A1 AR 082411A1
- Authority
- AR
- Argentina
- Prior art keywords
- vegfa
- sirna
- syrna
- aimed
- treatment methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
Abstract
El factor de crecimiento endotelial vascular A (VEGFA) es una señal química producida por células que estimulan el crecimiento de nuevos vasos sanguíneos y la sobreexpresión del VEGFA puede llevar a condiciones fisiológicas no deseadas. Mediante la identificación del nuevo siRNA y modificaciones que mejoran la habilidad de silenciar dicho siRNA in vivo se han preparado composiciones y métodos terapéuticos para tratar los problemas asociados con dicha sobreexpresión.Reivindicación 1: Un método para disminuir la expresión del VEGFA in vivo, que comprende la administración de un siRNA a un sujeto, en donde el siRNA comprende una secuencia que es una secuencia seleccionada de SEQ ID Nº 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, y 88.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36838510P | 2010-07-28 | 2010-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR082411A1 true AR082411A1 (es) | 2012-12-05 |
Family
ID=45527345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110102737A AR082411A1 (es) | 2010-07-28 | 2011-07-28 | siRNA DIRIGIDO AL VEGFA Y METODOS DE TRATAMIENTO IN VIVO |
Country Status (16)
Country | Link |
---|---|
US (2) | US8546349B2 (es) |
EP (1) | EP2598639A4 (es) |
JP (1) | JP2013539456A (es) |
KR (1) | KR20130095737A (es) |
CN (1) | CN103068981A (es) |
AR (1) | AR082411A1 (es) |
AU (1) | AU2011282902B2 (es) |
BR (1) | BR112013001918A2 (es) |
CA (1) | CA2804847A1 (es) |
CL (1) | CL2013000237A1 (es) |
MX (1) | MX2013000986A (es) |
RU (1) | RU2013102545A (es) |
TW (1) | TW201219041A (es) |
UY (1) | UY33533A (es) |
WO (1) | WO2012015775A2 (es) |
ZA (1) | ZA201300531B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2943571A4 (en) | 2013-01-08 | 2016-11-30 | Benitec Biopharma Ltd | TREATMENT OF AGE-RELATED MACULAR GENERATION |
AU2014255381A1 (en) | 2013-04-17 | 2015-10-08 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
TWI496595B (zh) * | 2013-06-07 | 2015-08-21 | Univ Nat Taiwan Ocean | 製備魚類核醣核酸試劑之方法 |
WO2015165030A1 (en) * | 2014-04-29 | 2015-11-05 | Microsoft Technology Licensing, Llc | Encoder-side decisions for sample adaptive offset filtering |
EP3294880A4 (en) * | 2015-05-15 | 2018-12-26 | Dharmacon, Inc. | Synthetic single guide rna for cas9-mediated gene editing |
US10883108B2 (en) | 2016-03-31 | 2021-01-05 | The Schepens Eye Research Institute, Inc. | Endomucin inhibitor as an anti-angiogenic agent |
GB201802404D0 (en) * | 2018-02-14 | 2018-03-28 | Univ Malta | Methods |
CA3096938A1 (en) * | 2018-04-10 | 2019-10-17 | Ottawa Hospital Research Institute | Microrna-based compositions and methods used in disease treatment |
CN114727967A (zh) * | 2019-09-06 | 2022-07-08 | 加利福尼亚大学董事会 | 核酸介导的治疗剂的递送 |
IL295445A (en) * | 2020-02-10 | 2022-10-01 | Alnylam Pharmaceuticals Inc | Preparations and methods for silencing vegf-a expression |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5641756A (en) | 1993-07-27 | 1997-06-24 | Hybridon, Inc. | Modified VEGF oligonucleotides |
US6410322B1 (en) | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
US6306829B1 (en) | 1995-12-08 | 2001-10-23 | Hybridon, Inc. | Modified VEGF oligonucleotides for treatment of skin disorders |
US5731294A (en) | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
WO1996000286A1 (fr) | 1994-06-27 | 1996-01-04 | Toagosei Co., Ltd. | Compose d'acide nucleique antisens |
US5830879A (en) | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
WO2002096927A2 (en) | 2001-05-29 | 2002-12-05 | Ribozyme Pharmaceuticals, Incorporated | Ribozyme based treatment of female reproductive diseases |
EP0865489A1 (en) | 1995-12-08 | 1998-09-23 | HYBRIDON, Inc. | Modified vegf antisense oligonucleotides |
AU2733697A (en) | 1996-04-17 | 1997-11-07 | Aronex Pharmaceuticals, Inc. | Antisense inhibitors of vascular endothelial growth factor (vegf/vpf) expression |
WO1998027425A1 (en) | 1996-12-19 | 1998-06-25 | Isis Pharmaceuticals, Inc. | Large-scale purification of full length oligonucleotides by solid-liquid affinity extraction |
JPH1142091A (ja) | 1997-07-25 | 1999-02-16 | Toagosei Co Ltd | アンチセンス核酸化合物 |
AUPP249298A0 (en) * | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
ES2226414T3 (es) | 1998-06-10 | 2005-03-16 | Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh | Estimulacion del sistema inmunitario. |
IL142583A0 (en) | 1998-11-06 | 2002-03-10 | Basf Ag | Inhibition of the formation of vascular hyperpermeability |
CA2422934A1 (en) | 2000-10-13 | 2002-04-18 | Institut De Cardiologie De Montreal | Antisense oligonucleotides directed toward mammalian vegf receptor genes and uses thereof |
AU2002305236A1 (en) | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent |
US20070021360A1 (en) | 2001-04-24 | 2007-01-25 | Nyce Jonathan W | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase |
WO2003070910A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US7517864B2 (en) * | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
FR2832154B1 (fr) | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
US20100113307A1 (en) | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA targeting vascular endothelial growth factor (VEGF) |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
WO2004076639A2 (en) * | 2003-02-26 | 2004-09-10 | Wyeth | Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus |
JP4605799B2 (ja) * | 2003-04-02 | 2011-01-05 | ダーマコン, インコーポレイテッド | Rna干渉において使用するための修飾ポリヌクレオチド |
JP2008167739A (ja) * | 2006-06-14 | 2008-07-24 | National Institute Of Advanced Industrial & Technology | Rna干渉効果が高い修飾型二本鎖rna |
CA2663601C (en) | 2006-09-22 | 2014-11-25 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by rna interference |
WO2008045576A2 (en) * | 2006-10-12 | 2008-04-17 | Yijia Liu | Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases |
US20080286866A1 (en) * | 2007-03-02 | 2008-11-20 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting vegf gene expression and uses thereof |
US20100216865A1 (en) * | 2007-09-12 | 2010-08-26 | Elias Jack A | MicroRNA COMPOSITIONS IN THE TREATMENT OF VEGF-MEDIATED DISORDERS |
US8188060B2 (en) * | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
KR101397407B1 (ko) * | 2008-03-05 | 2014-06-19 | 알닐람 파마슈티칼스 인코포레이티드 | Eg5 및 VEGF 유전자의 발현을 억제하기 위한 조성물 및 방법 |
SG171952A1 (en) * | 2008-12-04 | 2011-07-28 | Opko Ophthalmics Llc | Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
-
2011
- 2011-07-26 JP JP2013521887A patent/JP2013539456A/ja active Pending
- 2011-07-26 AU AU2011282902A patent/AU2011282902B2/en not_active Ceased
- 2011-07-26 KR KR1020137004590A patent/KR20130095737A/ko not_active Application Discontinuation
- 2011-07-26 WO PCT/US2011/045273 patent/WO2012015775A2/en active Application Filing
- 2011-07-26 RU RU2013102545/10A patent/RU2013102545A/ru not_active Application Discontinuation
- 2011-07-26 BR BR112013001918A patent/BR112013001918A2/pt not_active IP Right Cessation
- 2011-07-26 EP EP11813031.9A patent/EP2598639A4/en not_active Withdrawn
- 2011-07-26 CN CN201180036639XA patent/CN103068981A/zh active Pending
- 2011-07-26 MX MX2013000986A patent/MX2013000986A/es not_active Application Discontinuation
- 2011-07-26 US US13/190,797 patent/US8546349B2/en active Active
- 2011-07-26 CA CA2804847A patent/CA2804847A1/en not_active Abandoned
- 2011-07-27 UY UY0001033533A patent/UY33533A/es not_active Application Discontinuation
- 2011-07-27 TW TW100126492A patent/TW201219041A/zh unknown
- 2011-07-28 AR ARP110102737A patent/AR082411A1/es unknown
-
2013
- 2013-01-21 ZA ZA2013/00531A patent/ZA201300531B/en unknown
- 2013-01-24 CL CL2013000237A patent/CL2013000237A1/es unknown
- 2013-08-27 US US14/010,749 patent/US9150862B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20120029051A1 (en) | 2012-02-02 |
EP2598639A4 (en) | 2014-08-13 |
TW201219041A (en) | 2012-05-16 |
JP2013539456A (ja) | 2013-10-24 |
EP2598639A2 (en) | 2013-06-05 |
BR112013001918A2 (pt) | 2016-05-24 |
CA2804847A1 (en) | 2012-02-02 |
RU2013102545A (ru) | 2014-09-10 |
ZA201300531B (en) | 2014-03-26 |
AU2011282902A1 (en) | 2013-01-31 |
CN103068981A (zh) | 2013-04-24 |
CL2013000237A1 (es) | 2014-03-21 |
WO2012015775A2 (en) | 2012-02-02 |
US20140031414A1 (en) | 2014-01-30 |
MX2013000986A (es) | 2013-07-03 |
UY33533A (es) | 2012-02-29 |
AU2011282902B2 (en) | 2015-01-29 |
WO2012015775A3 (en) | 2012-08-09 |
US8546349B2 (en) | 2013-10-01 |
KR20130095737A (ko) | 2013-08-28 |
US9150862B2 (en) | 2015-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR082411A1 (es) | siRNA DIRIGIDO AL VEGFA Y METODOS DE TRATAMIENTO IN VIVO | |
WO2010065671A3 (en) | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf | |
WO2012071526A3 (en) | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds | |
MX2019005130A (es) | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente. | |
NZ609223A (en) | Vasoprotective and cardioprotective antidiabetic therapy | |
EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
JP2012041342A5 (es) | ||
MX2014004458A (es) | Hebra de acido hialuronico reticulado y metodos de uso de las mismas. | |
MX346002B (es) | Anticuerpos anti-vegf y sus usos. | |
RU2014146170A (ru) | Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации | |
IN2014MN01981A (es) | ||
AR082312A1 (es) | Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos | |
MX2010007887A (es) | Tratamiento y prevencion de condiciones cardiacas utilizando dos o mas isoformas del factor de crecimiento de hepatocitos. | |
NZ601919A (en) | Cell-scaffold constructs | |
WO2017043953A3 (es) | Proceso de obtención de un compuesto de aspersión de células endoteliales microvasculares de piel y células madre mesenquimales y su método de aplicación para la regeneración tisular | |
EA201490509A1 (ru) | Биосовместимый катетер | |
SG11201804755VA (en) | Method for manufacturing tissue/organ by using blood cells | |
Hu et al. | Autophagy protein 5 enhances the function of rat EPCs and promotes EPCs homing and thrombus recanalization via activating AKT | |
WO2010093993A3 (en) | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance | |
RU2015112121A (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
WO2013078376A3 (en) | Isoxazole treatments for diabetes | |
RU2013121802A (ru) | Профилактический или терапевтический агент для лечения фиброза | |
MD3988C2 (ro) | Remediu regenerator pentru tratamentul plăgilor şi combustiilor | |
TW201613621A (en) | Composition for promoting growth of dermal papilla cells, pharmaceutical composition, and preparation method thereof | |
CN102533982A (zh) | 人klf8基因在肿瘤治疗中的新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |